 |
|
|
|
|
|
|
|
|
|
| |
At the March 15, 2006 RAC meeting, the RAC discussed the conduct of risk assessments and determination of containment for lentiviral vector research. The NIH Guidelines for Research Involving Recombinant DNA Molecules do not directly address the use of lentiviral vectors. To provide additional guidance to Institutional Biosafety Committees and investigators, OBA organized a working group of RAC and ad hoc reviewers with virology and biosafety expertise to develop some general criteria to be considered when conducting risk assessments for research involving lentiviral vectors.
|
|
|
| |
Guidance on Biosafety Considerations for Research with Lentiviral Vectors
|
|
| |
|
|
| |
Webcast
and
Slides
|
|
|
| |
Minutes of March 2006 RAC Meeting
|
|
|
| |
Minutes of June 2006 RAC Meeting
|
|
|
| |
Minutes of September 2006 RAC Meeting
|
|
| |
|
|
| |
Reviews and Recommendations: |
|
|
| |
 |
Nikunj V. Somia, Ph.D.
RAC Member
Molecular Genetics Institute
University of Minnesota, Twin Cities
|
|
|
| |
|
Stephen Dewhurst, Ph.D.
RAC Member
Department of Microbiology and Immunology
University of Rochester Medical Center
|
|
|
| |
|
Naomi Rosenberg, Ph.D.
RAC Member
Department of Pathology
Tufts University, School of Medicine
|
|
|
| |
|
LouAnn C. Burnett, M.S., CBSP
Ad-Hoc Expert
Environmental Health and Safety Department
Vanderbilt University
|
|
| |
|
Top of Page |
